In HCC, several studies have proven sorafenib can enhance antitumor responses through increasing the proportion of tumor-specific effector CD8+ T cells and reducing the proportion of exhausted or immunosuppressive immune cells such as PD-1-expressing CD8+ T cells and Foxp3+ Tregs (103, 104). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.